Castellani: Editorial belittles value of cancer drugs to patients

Careful policies are needed to support innovation and boost the access and affordability of drugs for patients, PhRMA President and CEO John J. Castellani writes in response to a May 2 editorial on the price of leukemia treatments. The editorial did not address the value of new drugs, realities of how they are developed nor the system by which they they are reimbursed, Castellani writes. "Since 1980, life expectancy for cancer patients has increased by about three years, and about 80 percent of those gains are thanks to new treatments. Each new cancer medicine, whether it extends a life by months or years, helps build cumulative advances that drive medical discovery," he writes.

View Full Article in:

New York Times (tiered subscription model), The